{
    "nct_id": "NCT03187184",
    "official_title": "Implementing Preemptive Pharmacogenomic Testing for Colorectal Cancer Patients in a Community Oncology Clinic",
    "inclusion_criteria": "1. Histologically proven Stage 2-4 colon or rectal adenocarcinoma with an anticipated need for chemotherapy, which may include neoadjuvant, adjuvant or palliative treatment, and may include oral or intravenous chemotherapy.\n2. Adequate organ function and performance status to receive chemotherapy as determined by the treating physician.\n3. Age ≥ 18 years.\n4. Ability to understand and the willingness to sign a written informed consent documented.\n5. Patients must sign consent within 7 days of the physician visit for newly diagnosed or recurrent colorectal cancer when a patient is initially felt to be a candidate for chemotherapy.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Patients received prior chemotherapy for colorectal cancer in the last 12 months.\n2. Patients received prior OneOme RightMed® pharmacogenomic testing.",
    "miscellaneous_criteria": ""
}